ZyVersa Therapeutics Files 8-K with Material Agreement
Ticker: ZVSA · Form: 8-K · Filed: Jul 9, 2025 · CIK: 1859007
| Field | Detail |
|---|---|
| Company | Zyversa Therapeutics, Inc. (ZVSA) |
| Form Type | 8-K |
| Filed Date | Jul 9, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, equity-sale, filing
TL;DR
ZyVersa Therapeutics (ZVSA) filed an 8-K on July 8, 2025, reporting a material definitive agreement and equity sales.
AI Summary
On July 8, 2025, ZyVersa Therapeutics, Inc. entered into a Material Definitive Agreement. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. ZyVersa Therapeutics, Inc. was formerly known as Larkspur Health Acquisition Corp. until April 26, 2021.
Why It Matters
This 8-K filing indicates significant corporate activity, including a material definitive agreement and equity sales, which could impact the company's financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can introduce financial and regulatory risks.
Key Players & Entities
- ZyVersa Therapeutics, Inc. (company) — Registrant
- Larkspur Health Acquisition Corp. (company) — Former company name
- July 8, 2025 (date) — Date of earliest event reported
- April 26, 2021 (date) — Date of name change
FAQ
What is the nature of the Material Definitive Agreement entered into by ZyVersa Therapeutics, Inc. on July 8, 2025?
The filing states that ZyVersa Therapeutics, Inc. entered into a Material Definitive Agreement on July 8, 2025, but the specific details of this agreement are not provided in the provided text.
What type of equity securities were sold in the unregistered sales reported by ZyVersa Therapeutics, Inc.?
The filing mentions unregistered sales of equity securities, but the specific type and amount of securities are not detailed in the provided text.
What are the key financial statements and exhibits being filed with this 8-K?
The filing indicates that financial statements and exhibits are being filed, but the specific content of these documents is not described in the provided text.
When did ZyVersa Therapeutics, Inc. change its name from Larkspur Health Acquisition Corp.?
ZyVersa Therapeutics, Inc. changed its name from Larkspur Health Acquisition Corp. on April 26, 2021.
What is the principal executive office address for ZyVersa Therapeutics, Inc.?
The principal executive office address for ZyVersa Therapeutics, Inc. is 2200 N. Commerce Parkway, Suite 208, Weston, Florida 33326.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 9, 2025 regarding ZyVersa Therapeutics, Inc. (ZVSA).